author-photo

Hao Zhao

University of Texas MD Anderson Cancer Center

50

Papers

3562

Citations

Citation Trend

Filter By

Papers (31) Sort By

Journal Conference Others

B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response

2020 Nature
Show All
- Source
- Cite
- Save
Citations (545)
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

2020 Science Translational Medicine
Show All
- Source
- Cite
- Save
Citations (46)
Immune Profiling of Human Tumors Identifies CD73 as a Combinatorial Target in Glioblastoma

2020 Nature Medicine
Show All
- Source
- Cite
- Save
Citations (95)
A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Characterization and comparison of GITR expression in solid tumors

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (11)
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities

2019 Proceedings of the National Academy of Sciences of the United States of America
Show All
- Source
- Cite
- Save
Citations (52)
Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy

2018 Journal of Clinical Investigation
Show All
- Source
- Cite
- Save
Citations (97)
A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx).

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Abstract CT083: Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)